New drug cocktail aims to boost head and neck cancer treatment before and after surgery
NCT ID NCT07707167
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether giving a combination of two drugs (becotatug vedotin and putlimab) before surgery, followed by radiotherapy and more putlimab after surgery, can improve outcomes for people with locally advanced head and neck cancer. The trial enrolls about 35 participants whose cancer can be surgically removed. The goal is to see how well the cancer responds to this treatment plan and to monitor any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of an experimental antibody-drug conjugate (becotatug vedotin) and an immunotherapy drug (putlimab), plus radiotherapy
- What this could lead to
- If successful, this approach could become a new standard perioperative treatment for locally advanced head and neck cancer, potentially improving survival and reducing the chance of cancer returning.
- What could go wrong
- This is an early-phase exploratory study with only 35 participants, so results may not apply to all patients. The combination may cause significant side effects, and the added benefit over existing treatments is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LA HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Cancer Hospital
Nanjing, China